Feasibility Trials of the NIH Music-based Interventions Toolkit for Brain Disorders of Aging (R34 Clinical Trial Required)
Funding Opportunity PAR-24-168 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to reissue PAR-24-256 "Feasibility Trials of the NIH Music-based Interventions Toolkit for Brain Disorders of Aging (R34 Clinical Trial Required)" in order to support proof-of-concept feasibility trials guided by the NIH Music-based Interventions (MBI) Toolkit for research on brain disorders of aging. These early stage clinical trials will generate evidence supporting the validity of the NIH MBI Toolkits guiding principles as well as the necessary pilot data to assess the feasibility of...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 10, 2024 Category: Research Source Type: funding
Notice of Change in Eligibility to Part I for RFA-DK-23-001 "A Consortium for Gut-Brain Communication in Parkinsons Disease (U24 Clinical Trial not allowed)"
Notice NOT-DK-23-030 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 22, 2023 Category: Research Source Type: funding
Notice of Change in Eligibility to Section III for RFA-DK-22-036 "A Consortium for Gut-Brain Communication in Parkinsons Disease (U01 Clinical Trial Not Allowed)"
Notice NOT-DK-23-031 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 17, 2023 Category: Research Source Type: funding
Feasibility Trials of the NIH Music-based Interventions Toolkit for Brain Disorders of Aging (R34 Clinical Trial Required)
Funding Opportunity PAR-23-256 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support proof-of-concept feasibility trials guided by the NIH Music-based Interventions (MBI) Toolkit for research on brain disorders of aging. These early phase clinical trials will generate evidence supporting the validity of the NIH MBI Toolkits guiding principles as well as the necessary pilot data to design a subsequent clinical efficacy or effectiveness study (or pragmatic clinical trial) using music-based interventions in the context of brain disorders of aging, including but ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 7, 2023 Category: Research Source Type: funding
A Consortium for Gut-Brain Communication in Parkinsons Disease (U24 Clinical Trial not allowed)
Funding Opportunity RFA-DK-23-001 from the NIH Guide for Grants and Contracts. Parkinsons disease (PD) is the second most common and fastest growing neurodegenerative disorder, with approximately 60,000 Americans diagnosed annually. PD symptoms are not limited to motor dysfunction and more than 50% of patients who develop PD often have a history of bowel complaints affecting nearly all parts of the gastrointestinal (GI) system. These SI symptoms often precede the onset of motor symptoms, indicating that GI dysfunction may be an early manifestation of the disease and the gut may be an unexplored diagnostic and/or therape...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 31, 2023 Category: Research Source Type: funding
A Consortium for Gut-Brain Communication in Parkinsons Disease (U01 Clinical Trial Not Allowed)
The objective of this consortium is to accelerate research on the role gastrointestinal (GI) symptoms and changes in gut-brain communication in the initiation and pathogenesis of Parkinsons disease in order to facilitate development and validation of innovative early-phase GI-based diagnostic tools and biomarkers for PD. The research centers of the GBPDC will serve as sites for enrollment of PD patients with and without GI symptoms, patients with GI symptoms considered to be at risk for PD, and healthy age-matched controls for laboratory-based studies on biological samples obtained from these patients. The NIDDK strongly e...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 31, 2023 Category: Research Source Type: funding
Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed)
Funding Opportunity RFA-NS-24-009 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) supports the optimization of promising genome editing-based therapeutic leads for Alzheimer's Disease-Related Dementias (ADRD), towards IND-enabling studies. Specifically, it supports the characterization and optimization of therapeutic lead(s) that show promise as potential genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. At the end of the funding period, successful projects will have optimized a genome editing therapeutic candidate with demonstr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 26, 2023 Category: Research Source Type: funding
Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed)
Funding Opportunity RFA-NS-24-010 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant? Alzheimer's and related dementias: frontotemporal degeneration (FTD, including Picks disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinsons disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). This FOA covers four stages of early therapy dis...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 15, 2023 Category: Research Source Type: funding
Notice of Intent to Publish a Funding Opportunity Announcement for A Consortium for Gut-Brain Communication in Parkinsons Disease (U24 Clinical Trial Not Allowed)
Notice NOT-DK-23-007 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 24, 2023 Category: Research Source Type: funding
Notice of Intent to Publish a Funding Opportunity Announcement for A Consortium for Gut-Brain Communication in Parkinsons Disease (U01 Clinical Trial Not Allowed)
Notice NOT-DK-23-006 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 24, 2023 Category: Research Source Type: funding
Optimization of Genome Editing Therapeutics for Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) (U01 - Clinical Trials Not Allowed)
Funding Opportunity RFA-NS-23-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the optimization of promising genome editing-based therapeutic leads for Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD), towards IND-enabling studies. Specifically, it supports the characterization and optimization of therapeutic lead(s) that show promise as potential genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. At the end of the funding period, successful projects will have optimized a genome editing therap...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 24, 2022 Category: Research Source Type: funding
Early-Stage Therapy Development for ADRD (R61/R33 Clinical Trial Not Allowed)
Funding Opportunity RFA-NS-22-059 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant? Alzheimer's and related dementias: frontotemporal degeneration (FTD, including Picks disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinsons disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). This FOA covers four stages of early therapy dis...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 2, 2022 Category: Research Source Type: funding
Functional Target Validation for Alzheimer's Disease-Related Dementias (ADRDs) (R61/R33 Clinical Trial Not Allowed)
Funding Opportunity RFA-NS-22-055 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose the comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer's Disease-Related Dementias (ADRDs). This FOA seeks to promote critical target validation approaches to help de-risk subsequent translational research and accelerate the advancement of novel therapies for ADRD. Target(s) or molecular pathway(s) to be considered for validation must have been already identified using tissue expression or genetic data generated in human samples. In its initial phase, ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 21, 2022 Category: Research Source Type: funding
Extracellular RNA Sequencing Research Resource for the Accelerating Medicines Partnership Parkinsons Disease (AMPPD) (R24 - Clinical Trial Not Allowed)
Funding Opportunity RFA-NS-23-014 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks applicants experienced in the isolation and sequencing of RNA from brain-derived extracellular vesicles to develop a research resource for the Accelerating Medicines Partnership in Parkinson's Disease (AMP PD). Approximately 2400 blood samples will be provided for this project from existing Parkinson's disease and normal control cohorts that already have longitudinal clinical and sequencing data that is publicly available to interested researchers. It is intended that this resource will become...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 8, 2022 Category: Research Source Type: funding
Biomarkers for the Lewy Body Dementias (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-NS-22-001 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven clinical research applications that are focused on discovering novel diagnostic, prognostic, and/or therapeutic biomarkers for the Lewy Body Dementias (LBD).Biomarker research must be conducted in patients with LBD, must follow Parkinson's Disease Biomarker Program (PDBP) protocols for clinical assessment and biospecimen collection,and must be broadly shareable through the PDBP repositories. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 6, 2021 Category: Research Source Type: funding
